Перейти к содержанию

Amneal Pharmaceuticals, Inc. (AMRX) stock: revenue, earnings & dividend

Amneal Pharmaceuticals, Inc. (AMRX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener AMRX · Nasdaq Pharma & Biotech US-NJ

Key figures

Fiscal year
2025
Revenue
3.02 bn $
Revenue growth
8.1 %
Revenue growth 5y (p.a.)
8.7 %
Net income
72.1 m $
Net margin
2.4 %
Operating margin
13.1 %
Earnings per share (diluted)
0.22 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
3.68 bn $
Equity
-70.79 m $
Equity ratio
-1.9 %
Return on equity
–
Cash
282 m $
Operating cash flow
340 m $
Free cash flow
270 m $
Shares outstanding
348,412,726

History

Revenue by fiscal year

2016 1.02 bn $
2017 1.03 bn $
2018 1.66 bn $
2019 1.63 bn $
2020 1.99 bn $
2021 2.09 bn $
2022 2.21 bn $
2023 2.39 bn $
2024 2.79 bn $
2025 3.02 bn $

Net income by fiscal year

2016 0 $
2017 0 $
2018 -19.74 m $
2019 -603.57 m $
2020 67.8 m $
2021 13.2 m $
2022 -270.58 m $
2023 -83.99 m $
2024 -116.89 m $
2025 72.1 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20253.02 bn $72.1 m $0.22 $–340 m $
20242.79 bn $-116.89 m $-0.38 $–295 m $
20232.39 bn $-83.99 m $-0.48 $–346 m $
20222.21 bn $-270.58 m $-0.86 $–65.1 m $
20212.09 bn $13.2 m $0.07 $–242 m $
20201.99 bn $67.8 m $0.61 $–379 m $
20191.63 bn $-603.57 m $-2.74 $–1.71 m $
20181.66 bn $-19.74 m $-0.16 $–250 m $
20171.03 bn $0 $––234 m $
20161.02 bn $0 $––115 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)